AstraZeneca sets sights on $80B in revenue by 2030
Bio Pharma Dive
MAY 21, 2024
The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.
Tue.May 21, 2024
310 
Roche’s PI3K inhibitor secures breakthrough status in breast cancer
Pharmaceutical Technology
MAY 21, 2024
Roche announced an FDA breakthrough therapy designation for its inavolisib/Ibrance combination therapy.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AltruBio lands up to $225M after shift to immune drug research
Bio Pharma Dive
MAY 21, 2024
Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.
Eerie Personality Changes Sometimes Happen After Organ Transplants
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 21, 2024
The idea that the heart contains the very ‘essence’ of a person might be more than just a spiritual concept. Ever since the first human heart transplants back in 1967, patients have reported, often reluctantly, some eerie and inexplicable changes to their personalities.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AstraZeneca’s $80B sales plan leans on cancer drug expansion
Bio Pharma Dive
MAY 21, 2024
The U.K. drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.
Big Pharma Layoffs by the Thousands: Are Bayer and BMS Harbingers of More?
BioSpace
MAY 21, 2024
Patent cliffs and other factors may lead other large drugmakers to embrace similar cost-cutting measures, experts tell BioSpace.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Lilly collaborates with Aktis to strengthen radiopharma portfolio
Pharmaceutical Technology
MAY 21, 2024
Aktis will receive $60m in an upfront payment from Lilly, with the biotech eligible for up to $1.1bn in milestone payments and royalties.
Lilly partners with Aktis, deepening radiopharma investment
Bio Pharma Dive
MAY 21, 2024
The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.
Pheon cashes in on ADC trend and raises $120m in Series B
Pharmaceutical Technology
MAY 21, 2024
The UK-based company plans to use the proceeds for financing the proof-of-concept clinical trials for its ADC pipeline.
AstraZeneca, on fast track of growth, sets revenue target at $80B by 2030
Fierce Pharma
MAY 21, 2024
A decade ago, with AstraZeneca in decline and some investors urging the drugmaker to sell out to Pfizer, new CEO Pascal Soriot presented an audacious plan to hike revenue to $45 billion by 2023. | After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030.
Larimar resumes nomlabofusp programme after FDA lifts partial hold
Pharmaceutical Technology
MAY 21, 2024
Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.
AstraZeneca sets lofty target of $80bn in revenues by 2030
pharmaphorum
MAY 21, 2024
AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.
Glenmark to market BeiGene’s oncology medicines in India
Pharmaceutical Technology
MAY 21, 2024
Glenmark has entered into an exclusive agreement with BeiGene to market and distribute two Beigene oncology medicines in India.
FDA competition seeks digital endpoints for Parkinson’s
pharmaphorum
MAY 21, 2024
FDA is asking artificial intelligence teams to develop a digital endpoint tool to study freezing of gait, a symptom of Parkinson’s that can have a serious impact on patients.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
AmplifyBio and Xcell enter TCR T-cell therapy manufacturing deal
Pharmaceutical Technology
MAY 21, 2024
AmplifyBio and Xcell Biosciences have announced a strategic collaboration to manufacture engineered T-cell receptor (TCR) therapies.
NIHR awards HealthTech Research Centre Network £5m to advance health innovations
Pharma Times
MAY 21, 2024
The network will support the development, evaluation and adoption of innovative health and care technology
AstraZeneca to establish $1.5bn ADC production site in Singapore
Pharmaceutical Technology
MAY 21, 2024
AstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to the production of antibody drug conjugates.
NHS addresses shortage of ethnic organ and blood donors with £600,000 funding
Pharma Times
MAY 21, 2024
The funding aims to reduce health inequalities in these groups and save more lives
FDA grants approval for two Eylea biosimilars for eye conditions
Pharmaceutical Technology
MAY 21, 2024
The US FDA has approved Yesafili and Opuviz, two interchangeable biosimilars to Eylea, for macular degeneration and other eye conditions.
The commercialisation of quantum science in pharma
pharmaphorum
MAY 21, 2024
In today’s podcast, web editor Nicole Raleigh speaks with PASQAL’S technical business developer Europe, Krisztian Benyo, PhD, about the pharma applications and commercialisation of quantum science.
Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state
Fierce Pharma
MAY 21, 2024
As Incyte Corporation continues its growth momentum thanks to JAK inhibitors Jakafi and Opzelura, the company is bringing its U.S. | Incyte revealed plans to purchase buildings at 1100 North King Street and 1100 North French street in downtown Wilmington, Delaware, where the company got its start back in 2002.
Closing the bipolar diagnosis gap for Black Americans
pharmaphorum
MAY 21, 2024
Despite the rate of bipolar disorder being the same among Black Americans as other Americans, there exists a significant disparity in diagnosis and subsequent treatment. Many Black Americans with bipolar disorder remain undiagnosed and untreated.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
New patent for Merck Sharp drug BELSOMRA
Drug Patent Watch
MAY 21, 2024
Annual Drug Patent Expirations for BELSOMRA Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier.
EU rules PTC’s Duchenne drug can stay on the market
pharmaphorum
MAY 21, 2024
Going against the advice of the CHMP, the EU has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy should stay on the market
Lilly pads case for mirikizumab in its next potential indication in Crohn's disease
Fierce Pharma
MAY 21, 2024
Following last year’s hard-won ulcerative colitis nod for Eli Lilly’s Omvoh, also known as mirikizumab, the Indianapolis-based drugmaker is padding the case for its antibody’s next potential immuno | Following last year’s hard-won ulcerative colitis nod for Eli Lilly’s Omvoh, also known as mirikizumab, the Indianapolis-based drugmaker is padding the case for its antibody’s next potential immunology approval.
Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition
BioSpace
MAY 21, 2024
Days after backing out of two Ionis-partnered neuro programs, Biogen has inked a potential $1.8 billion buy of Human Immunology Biosciences and boosting its late-stage immunology pipeline.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Internal budgets ‘holding back pharma’s digital evolution’
pharmaphorum
MAY 21, 2024
Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.
9 Top Biopharma CEO-to-Employee Pay Gaps
BioSpace
MAY 21, 2024
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
Plants and vaccine adjuvants: BSI’s sustainable trees in a lab
pharmaphorum
MAY 21, 2024
Discover how the Quillaja saponaria tree is revolutionising vaccine development as a sustainable, natural adjuvant. Learn about BSI's innovative work harnessing the power of this remarkable plant.
Wyden Targets Pfizer in Ongoing Pharma Tax Investigation in Letter to CEO
BioSpace
MAY 21, 2024
As part of an ongoing Senate investigation into pharma companies’ tax rates, Sen. Ron Wyden (D-Ore.) has asked Pfizer CEO Albert Bourla to explain irregularities in its reported revenues, losses and taxes paid.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content